Press Release

Printer Friendly Version View printer-friendly version
<< Back
Auris Medical to Announce Third Quarter 2014 Financial Results and Host Conference Call on Wednesday, December 3, 2014

ZUG, Switzerland, Dec. 1, 2014 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ: EARS) today announced that it will release its financial results for the third quarter ended September 30, 2014, on Wednesday, December 3, 2014. Following the announcement, Auris Medical's management will host a live conference call and webcast at 8:00 a.m. Eastern Time (2:00 p.m. Central European Time) to discuss Auris Medical's financial results for the second quarter and provide a general business update.

About Auris Medical

Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland.
 
Contact:

Dr. Thomas Meyer, Chairman and CEO, +41 41 729 71 94, ear@aurismedical.com

HUG#1875559

Auris Medical AG logo

Auris Medical AG